Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.

Trial Profile

Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2014

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 06 Feb 2014 Results published in the Journal of Urology.
    • 11 Sep 2013 Planned number of patients changed from 274 to 315 as reported by German Clinical Trials Register record.
    • 29 Aug 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004074).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top